The global cord blood banking services market is projected to grow from USD 33.85 billion in 2025 to USD 49.85 billion by 2031, with a CAGR of 6.84%. Growth is driven by increasing awareness of stem cell therapies, advancements in regenerative medicine, and expanding clinical applications in treating hematological and genetic disorders. North America leads with 39.54% market share, while Asia-Pacific emerges as a high-growth region.

Carterra Inc. announced the launch of the Carterra Vega, an industry-first 48-channel High-Throughput Surface Plasmon Resonance (HT-SPR) platform that delivers 12-fold higher throughput than competing systems. The platform enables primary screening of large molecular libraries with high-resolution binding data, capable of screening over 20,000 small molecule interactions per day. The first unit is scheduled for shipment in Q1 2026 to a top 10 pharmaceutical company.

U.S. stock futures declined on Tuesday ahead of December CPI data release. Major indices were trading lower with the S&P 500 down 0.12% and Nasdaq 100 down 0.19%. Key stocks in focus include Alphabet reaching $4 trillion market value, JPMorgan preparing to report Q4 earnings, Five9 expanding its Google Cloud partnership, and Revvity rising 4.92% after positive earnings guidance. Markets are pricing in a 95% likelihood of the Federal Reserve maintaining current interest rates in January.

Wall Street extended its record-setting streak with major indices hitting all-time highs after a breakthrough in US-China trade negotiations. Trade tensions eased with potential tariff threats averted and promising discussions between diplomatic representatives.

Revvity reported Q2 earnings beating estimates but lowered fiscal year 2025 guidance due to challenging macroeconomic conditions and China's new hospital laboratory reimbursement policy, which is impacting its immunodiagnostics business.

Revvity reported Q2 2025 financial results with $720 million revenue, exceeding estimates, but experiencing margin compression and slight earnings decline due to tariff pressures and challenging market conditions.

The global CRISPR gene editing market is projected to grow from USD 4.15 billion in 2024 to USD 16.47 billion by 2034, driven by technological advancements, increasing investments, and growing applications in biotechnology and healthcare.

The metastatic colorectal cancer clinical trial pipeline is accelerating, with over 150 pharmaceutical companies rigorously developing drugs for market entry. This indicates a positive sentiment for the industry as it aims to address the rising incidence of the disease.

The high content screening/imaging (HCS/I) market is projected to reach $5.1 billion by 2029, growing at a CAGR of 8.4%. Increasing R&D budgets and technological advances in HCS/I, such as AI integration, automation, and 3D cell models, are driving the market growth.

The neurogenomics market is projected to reach $4.68 billion by 2031, driven by declining sequencing costs, increasing prevalence of neurological disorders, and advancements in sequencing technologies. Key players include Illumina, Thermo Fisher Scientific, F. Hoffmann-La Roche, and others.

The global infectious disease diagnostics market is projected to reach $43.09 billion by 2031, growing at a CAGR of 8.20% during the forecast period. The market is driven by advancements in diagnostic technologies, rising cases of infectious diseases, and increased R&D funding.

The global CRISPR-based gene editing market is expected to reach $9.14 billion by 2030, driven by advancements in CRISPR technology, increasing prevalence of genetic disorders, and growing investments in biotechnology research.